Disparities in the Use of SGLT2 Inhibitors and Glucagon-like Peptide-1 Receptor Agonists in Adults With CKD in the United States
Related Posts
Gebremariam T, Gu Y, Patterson H, Youssef E, Alkhazraji S, Elsayed T, Wiederhold NP, Ibrahim AS. Efficacy assessments of SF001, a next-generation polyene antifungal, in[...]
Marshalek JP, Qing X, Tomassetti S. CD19 Expression in B-Cell Lymphomas and Clinical Considerations in the Evolving Landscape of CD19-Targeted Therapy. World J Oncol. 2025[...]
Iskander B, Punnanithinont N, Kambalapalli S, Ichikawa K, Kinninger A, Krishnan S, Lakshmanan S, Roy S, Budoff M. Racial differences in atherosclerosis and coronary plaque[...]